Acute myocardial infarction homepage

Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Phase III COMPASS study shows Xarelto (rivaroxaban)+ aspirin significantly reduced major CV events.- Janssen Research Development + Bayer HealthCare.

Results from the pivotal Phase III COMPASS study found that the Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily) plus...

Added 26 days ago Drug news

Sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial of Brilinta demonstrated a 29% risk reduction in CV death.- AstraZeneca.

AstraZeneca announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk...

Added 2 months ago Drug news

Study of PCI patients with Impella 2.5 heart pump published in Journal of Interventional Cardiology- Abiomed

Abiomed announced the publication of a peer-reviewed retrospective study on hemodynamic support with the Impella 2.5 heart pump. The study...

Search all news articles for Acute myocardial infarction

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

Visit Hyperammonaemia

European Guidelines for the management of acute coronary syndromes in patients presenting wihout persistent ST-segment elevation

The present document deals with the management of patients with suspected NSTE-ACS, replacing the document first published in 2000 and...

Added 2 years ago

ESC/EACTS Guidelines on Myocardial Revascularisation

In 2014, coronary artery bypass grafting (CABG) celebrates the 50th anniversary of the first procedures performed in 1964. Thirteen years...

Added 2 years ago

MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction

Myocardial infarction (MI) is one of the most dramatic presentations of coronary artery disease. It is usually caused by blockage...

Added 3 years ago

Search all guidelines for Acute myocardial infarction

Cangrelor: A New Route for P2Y12 Inhibition.

Antiplatelet therapy with a P2Y12 inhibitor is a key component of treatment for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Added 3 months ago

The Association Between Testosterone Use and Major Adverse Cardiovascular Events (MACE): An Exploratory Retrospective Cohort Analysis of Two Large, Contemporary, Coronary Heart Disease Clinical Trials

The cardiovascular (CV) safety profile of testosterone replacement therapy (TRT) in men is uncertain, particularly in older individuals with pre-existing coronary heart disease (CHD)

Added 4 months ago

Risk of myocardial infarction in older men receiving testosterone therapy.

Testosterone therapy for older men has increased substantially over the past decade. Research on the effects of testosterone therapy on cardiovascular outcomes has yielded inconsistent results.

Added 6 months ago

Search all journal articles for Acute myocardial infarction

Doctor in public health and health protection. Particular interests in vaccination (editor of journal Vaccines in Practice) and health informatics/intelligence. I blog and post in a personal capacity: nothing I write here should be assumed to represent the views of anybody other than ... Read more

The advance decision not to attempt cardiopulmonary resuscitation

Decisions to start cardiopulmonary resuscitation (CPR), or to decide in advance to issue a "do not attempt (cardiopulmonary) resuscitation" (DNAR) notice have always been a hot topic in clinical medicine. It may have become even more so since a recent (June 2014) court decision. This post discusses some of the issues and legalities around DNAR decisions.